Physician profile
Stephen P Chen
NPI 1205821477
$393,623.41
in general payments reported to CMS, 2019-2025
40 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $21K · 2021: $33K · 2022: $84K · 2023: $89K · 2024: $59K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Food and Beverage: $13K · Travel and Lodging: $3,805 · Honoraria: $2,000 · Consulting Fee: $665 · Education: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200,253.01 |
| Food and Beverage | $13,357.88 |
| Travel and Lodging | $3,804.97 |
| Honoraria | $2,000.00 |
| Consulting Fee | $665.00 |
| Education | $618.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $216,452.95 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $105,031.63 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28,967.99 | 2019-2025 | Ofev, Stiolto Respimat, Jardiance |
| Mylan Specialty L.P. | $12,435.66 | 2019-2024 | Yupelri, Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $11,224.65 | 2019-2024 | |
| Abbvie INC. | $7,943.39 | 2019-2025 | |
| Verona Pharma, INC. | $2,714.78 | 2025 | Ohtuvayre |
| Allergan, INC. | $2,027.17 | 2019-2020 | |
| Viatris Specialty LLC | $1,437.09 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $999.03 | 2019-2025 | Winrevair, Zerbaxa, Dificid |
| Actelion Pharmaceuticals US, INC. | $840.65 | 2019-2025 | Uptravi, Opsumit |
| Genentech USA, INC. | $475.41 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $455.97 | 2019-2025 | Dupixent |
| Harmony Biosciences LLC | $343.15 | 2020-2023 | Wakix |
| Genzyme Corporation | $300.56 | 2022-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $236.44 | 2019-2025 | Tyvaso, Orenitram, Tyvaso |
| Pulmonx Corporation | $216.20 | 2019-2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Insmed, INC. | $189.48 | 2019-2024 | Arikayce |
| Tepha INC | $163.17 | 2020 | |
| Intuitive Surgical, INC. | $132.48 | 2023 | Da Vinci Surgical System |
| Electromed, INC. | $131.84 | 2022-2023 | Smartvest |
| Abiomed | $125.00 | 2024 | Impella |
| Novo Nordisk INC | $120.19 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $101.33 | 2019-2024 | Tezspire |
| Sunovion Pharmaceuticals INC. | $82.33 | 2019-2022 | |
| Advanced Respiratory, INC | $71.50 | 2021 | |
| Lilly USA, LLC | $62.49 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Shionogi INC | $62.14 | 2023-2024 | Fetroja |
| Philips North America LLC | $43.85 | 2021-2024 | (Ak6) Vest Therapy |
| Paratek Pharmaceuticals, INC. | $34.40 | 2024 | Nuzyra |
| Radius Health, INC. | $28.04 | 2019 | |
| Gilead Sciences, INC. | $27.31 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $25.44 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.41 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $20.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.82 | 2020 | |
| Idorsia Pharmaceuticals US INC | $17.33 | 2023 | Quviviq |
| Pfizer INC. | $13.88 | 2019 | |
| Baxter Healthcare | $13.84 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Circassia INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.